Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heart Failure | 16 | 2021 | 6638 | 1.52 | Why? |
| Myocardial Revascularization | 1 | 2017 | 267 | 0.58 | Why? |
| Weight Loss | 2 | 2018 | 826 | 0.58 | Why? |
| Shock, Cardiogenic | 2 | 2020 | 700 | 0.55 | Why? |
| Body Fluids | 1 | 2018 | 451 | 0.52 | Why? |
| Myocardial Infarction | 2 | 2020 | 3361 | 0.49 | Why? |
| Body Weight | 2 | 2018 | 1074 | 0.48 | Why? |
| Myocardium | 3 | 2021 | 2323 | 0.47 | Why? |
| Troponin I | 1 | 2020 | 1298 | 0.45 | Why? |
| Ventricular Dysfunction, Right | 1 | 2017 | 639 | 0.41 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.38 | Why? |
| New York City | 9 | 2020 | 7432 | 0.36 | Why? |
| Hospitalization | 12 | 2020 | 54280 | 0.31 | Why? |
| Cardiology | 1 | 2021 | 2873 | 0.31 | Why? |
| Hospice Care | 2 | 2018 | 347 | 0.25 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.25 | Why? |
| Cardiovascular Diseases | 4 | 2020 | 11497 | 0.24 | Why? |
| Patient Readmission | 2 | 2020 | 1543 | 0.19 | Why? |
| Aminobutyrates | 1 | 2020 | 142 | 0.19 | Why? |
| Liraglutide | 1 | 2018 | 47 | 0.18 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.18 | Why? |
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 56 | 0.18 | Why? |
| Benzazepines | 1 | 2017 | 49 | 0.17 | Why? |
| Tetrazoles | 1 | 2020 | 262 | 0.17 | Why? |
| Registries | 1 | 2017 | 12327 | 0.17 | Why? |
| Heart-Assist Devices | 3 | 2020 | 812 | 0.17 | Why? |
| Inpatients | 3 | 2021 | 5161 | 0.16 | Why? |
| Organ Transplantation | 2 | 2021 | 2616 | 0.15 | Why? |
| Post-Exposure Prophylaxis | 1 | 2020 | 472 | 0.15 | Why? |
| Prognosis | 8 | 2020 | 32490 | 0.15 | Why? |
| Health Resources | 2 | 2020 | 2592 | 0.15 | Why? |
| Hospital Mortality | 6 | 2020 | 22087 | 0.14 | Why? |
| Stroke Volume | 3 | 2020 | 2153 | 0.13 | Why? |
| Sarcoidosis | 1 | 2017 | 271 | 0.13 | Why? |
| Pulmonary Artery | 1 | 2020 | 803 | 0.13 | Why? |
| Heart Injuries | 1 | 2020 | 608 | 0.13 | Why? |
| New York | 1 | 2021 | 2488 | 0.12 | Why? |
| Heart Transplantation | 2 | 2020 | 1293 | 0.12 | Why? |
| Patients | 1 | 2020 | 1167 | 0.12 | Why? |
| Aged | 17 | 2021 | 215776 | 0.12 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 669 | 0.12 | Why? |
| Palliative Care | 2 | 2017 | 2665 | 0.12 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.12 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.12 | Why? |
| Coronavirus Infections | 11 | 2020 | 253789 | 0.11 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.11 | Why? |
| Hemorrhage | 2 | 2020 | 3013 | 0.11 | Why? |
| Ventricular Dysfunction, Left | 1 | 2019 | 993 | 0.11 | Why? |
| Anticoagulants | 3 | 2020 | 9563 | 0.10 | Why? |
| Male | 21 | 2021 | 367725 | 0.10 | Why? |
| Middle Aged | 18 | 2021 | 270681 | 0.10 | Why? |
| Humans | 32 | 2021 | 930598 | 0.10 | Why? |
| Pandemics | 15 | 2020 | 389249 | 0.10 | Why? |
| Electronic Health Records | 2 | 2020 | 3492 | 0.10 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.10 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.10 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.10 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.09 | Why? |
| Female | 18 | 2021 | 380317 | 0.09 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.09 | Why? |
| Cardiomyopathies | 1 | 2017 | 997 | 0.09 | Why? |
| Transplant Recipients | 2 | 2021 | 4982 | 0.09 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2020 | 88759 | 0.08 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.08 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.08 | Why? |
| Emergency Service, Hospital | 3 | 2020 | 14232 | 0.08 | Why? |
| Societies, Medical | 1 | 2021 | 6907 | 0.07 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Acute Kidney Injury | 2 | 2020 | 5762 | 0.06 | Why? |
| Myocarditis | 1 | 2019 | 2731 | 0.06 | Why? |
| Emergencies | 1 | 2017 | 4095 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Cause of Death | 1 | 2016 | 4823 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Incidence | 2 | 2020 | 25622 | 0.06 | Why? |
| Treatment Outcome | 4 | 2020 | 51732 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Length of Stay | 4 | 2020 | 11042 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.05 | Why? |
| Quality of Life | 2 | 2017 | 9820 | 0.05 | Why? |
| Hospitals, Private | 1 | 2020 | 198 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Valsartan | 1 | 2020 | 206 | 0.05 | Why? |
| Biphenyl Compounds | 1 | 2020 | 249 | 0.05 | Why? |
| Hematuria | 1 | 2020 | 284 | 0.05 | Why? |
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2017 | 6 | 0.05 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.05 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.04 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2020 | 757 | 0.04 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2020 | 418 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.04 | Why? |
| Hypotension | 1 | 2020 | 392 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Clinical Deterioration | 1 | 2020 | 473 | 0.04 | Why? |
| Risk Adjustment | 1 | 2020 | 730 | 0.04 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.04 | Why? |
| Adult | 7 | 2020 | 244371 | 0.04 | Why? |
| Hospitals, Urban | 1 | 2020 | 950 | 0.04 | Why? |
| Diuretics | 1 | 2016 | 326 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Leukocytes | 1 | 2020 | 1046 | 0.03 | Why? |
| Natriuretic Peptide, Brain | 1 | 2020 | 1215 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Cardiovascular Agents | 1 | 2017 | 663 | 0.03 | Why? |
| Hospitals | 2 | 2020 | 11793 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| United States | 4 | 2020 | 46150 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Case-Control Studies | 2 | 2020 | 17671 | 0.02 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.02 | Why? |
| Medicare | 1 | 2017 | 1048 | 0.02 | Why? |
| Peptide Fragments | 1 | 2020 | 2075 | 0.02 | Why? |
| Income | 1 | 2018 | 1564 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.02 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Home Care Services | 1 | 2017 | 1351 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2019 | 48226 | 0.02 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2016 | 6543 | 0.02 | Why? |
| Renal Dialysis | 1 | 2020 | 4358 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.02 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.02 | Why? |
| Survival Analysis | 1 | 2016 | 7592 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Databases, Factual | 1 | 2016 | 6248 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.01 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.01 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 5277 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2016 | 10649 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Intensive Care Units | 1 | 2018 | 29594 | 0.01 | Why? |
Lala's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(212)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_